Abstract Little is known about individuals' motivation, perception, and treatment beliefs towards the use of genetic information in risk estimates for coronary heart disease (CHD). In this study, participants at intermediate 10-year risk of CHD were randomized to receive either their estimated conventional risk score (CRS) alone, or a CRS and a genetic risk score (GRS), by a genetic counselor. Surveys on motivation to participate in and perception of genetic testing for CHD were administered at 3 months and treatment beliefs at 6 months following risk disclosure. Survey responses used Likert scales. Linear and logistic regression were used for analysis. Overall, motivation to participate in genomic clinical trials was favorable and did not differ between the CRS and GRS groups (16.95 ± 0.82 vs. 17.58 ± 0.83, p = 0.091), but participants who initially received their GRS indicated a greater desire to find ways to improve health as a reason for participation (OR: 0.53 (95%CI: 0.29, 0.94), p = 0.028). Perception of genetic testing was also favorable in both groups (15.29 ± 0.39 vs. 15.12 ± 0.40, p = 0.835). Participants who initially received their GRS were more inclined to recommend genetic testing to family and friends (9.95 ± 1.88 vs. 10.52 ± 2.17, p = 0.023). In the MI-GENES study, motivation to participate in and perception of genetic testing among study participants were overall favorable. Genetic risk disclosure was associated with increased motivation to recommend genetic testing to family and friends.
Introduction
Coronary heart disease (CHD) is the leading cause of mortality worldwide, imposing a major economic and resource burden on health systems (Finegold et al. 2013) . Conventional risk factors such as age, sex, smoking, cholesterol and hypertension are used to estimate CHD risk (Kullo and Cooper 2010; Wilson et al. 1998) , but a significant component of the risk may be due to genetic predisposition. The risk of CHD attributable to genetic factors has been estimated to be 40-60% (Chan and Boerwinkle 1994; Lloyd-Jones et al. 2004; Marenberg et al. 1994 ; R. Roberts 2015; R. Roberts and Stewart 2012; Zdravkovic et al. 2007 ). Multiple genetic variants associated with increased susceptibility to CHD have been discovered (Deloukas et al. 2013; Erdmann et al. 2009; Farrall et al. 2006; Schunkert et al. 2011) . Recent studies show that a genetic risk score (GRS) calculated from the cumulative effects of these variants can reclassify patients' CHD risk category assigned based on conventional risk factors (Brautbar et al. 2012; Ding et al. 2011; Ganna et al. 2013; Goldstein et al. 2014; Kraft and Hunter 2009; Mega et al. 2015; Thanassoulis et al. 2013; Tikkanen et al. 2013) . Use of statin therapy based on reclassification of CHD risk using a GRS appears promising for prevention of adverse outcomes (Mega et al. 2015) . Further progress in this area is expected with the establishment of the Precision Medicine Initiative (PMI) to spur research in genomic Electronic supplementary material The online version of this article (doi:10.1007/s10897-017-0092-9) contains supplementary material, which is available to authorized users. medicine (F. S. Collins and Varmus 2015; The White House 2015) . To support this anticipated progress and promote the incorporation of these advances in genetic testing in clinical care, it is important to understand the motivations of individuals participating in genetic testing research, including their likelihood to use and recommend genetic testing, as well as perceptions about genetic testing and beliefs about future related advances in treatments for CHD.
Despite the potential benefits of genetic testing, studies on familial long QT syndromes, hypertrophic cardiomyopathy, and hereditary cancer syndromes indicate that the uptake of genetic testing is low (Burns et al. 2016; Christiaans et al. 2008; Daly et al. 2016; Finlay et al. 2008; Willis et al. 2016) . Little is known about the motivation of the general public to utilize genetic testing for CHD risk and recommend testing to others. Motivation to use and recommend CHD genetic testing may indicate the perceived benefit of genetic testing. Studies on perception of genetic testing for asthma, diabetes, and hereditary cancer syndromes have shown that patients may have unrealistic or inaccurate perceptions about genetic testing (Calsbeek et al. 2007; Gollust et al. 2012; Hall et al. 2015) . Such perceptions range from high expectations, feelings of fatalism, personal privacy concerns, and social consequences including health insurability and losing employment opportunities. Conversely, positive beliefs about symptom control and finding a cure for CHD have been associated with participation in healthy behaviors (Petrie et al. 1996) . This suggests that beliefs about future advances in CHD management could associate with increased utilization of genetic testing for CHD. While reasons for the utilization of genetic testing in many diseases have been reported (Blanchette et al. 2014; Calsbeek et al. 2007; Erskine et al. 2014; Freedman et al. 2013; Gollust et al. 2012; Gupte et al. 2015; Leenen et al. 2016 ), these have not been investigated in the context of CHD. Such knowledge gaps necessitate studies to clarify the importance of these psychosocial variables, which may affect patient engagement in precision medicine.
We therefore investigated whether disclosure of GRS for CHD influenced motivation to participate in genetic testing research, motivation to utilize genetic testing and recommend testing to others, perceptions about genetic testing, and treatment optimism regarding CHD, as secondary outcomes of the MI-GENES (Myocardial Infarction Genes) study.
Methods

Study Design
The methodology and design of MI-GENES study have previously been described in detail (Kullo et al. 2016; Kullo et al. 2015) . In brief, the MI-GENES study is a randomized control trial, approved by Mayo Clinic IRB, assessing the effect of CHD genetic risk disclosure on LDL cholesterol levels. The secondary outcomes relevant to our study were survey measures of motivation, perception, and treatment beliefs regarding genetic risk disclosure for CHD.
The GRS was estimated based on 28 CHD susceptibility single nucleotide polymorphisms (SNP) not associated with blood pressure or lipids that have been identified in genome wide associations studies (GWAS) (Deloukas et al. 2013) . We classified individuals having a GRS > = 1.1, i.e. a 10% or greater increase in CHD risk, as having a high GRS and individuals having a GRS of <1.1 as having a low/average GRS (Fig. 1) . Conventional risk score (CRS) was estimated based on 10-year CHD risk using the Framingham risk equation (Wilson et al. 1998 ).
Participants
Participants enrolled in the Mayo Clinic Bio-Bank (n = 29,352) were prescreened for inclusion using the following eligibility criteria: 1) intermediate 10-year CHD risk based on CRS; 2) residents of Olmsted County, MN; 3) 45-65 years of age without known CHD or CHD risk equivalents; 4) not on statin therapy; 5) self-identified white ethnicity (as GRS was derived mainly from SNPs from GWAS of largely European ancestry); 6) absence of severe comorbidities with no major learning disabilities and able to provide informed consent. Out of 2026 eligible participants, a random subset of 1000 were genotyped for 28 SNPs, and 966 individuals were available after quality control. Subsequently, enrollment was targeted to include 110 participants in each high GRS (≥ 1.1) and low/ average GRS (<1.1) (Fig. 1) group. A computer-generated random sequence was performed controlling for age, gender, and positive family history for CHD, using previously described validated method (Pocock and Simon 1975) .
We were able to recruit 216 out of 220 target participants. A study coordinator invited these participants by phone to participate in the study and informed eligibility. At the first office visit, informed consent was obtained, and a new blood sample was drawn to obtain a baseline lipid panel and genotype CHD SNPs panel. At the second visit (6-10 weeks after the first visit), once the results of genotyping were available, participants were randomly assigned to receive either their CRS alone (in the CRS arm of the trial) or their CRS and GRS (in the GRS arm). A genetic counselor disclosed the CHD risk to each individual in a 30-min standardized scripted session. After 3 months of risk disclosure, at a third visit all participants completed surveys regarding motivation and perception. At 6 months from risk disclosure, at a fourth visit participants completed a survey on treatment beliefs. At this visit, participants in the CRS arm also received their GRS, but from a study coordinator rather than a genetic counselor. The study coordinator used the same standardized scripted material to disclose the genetic risk. These participants then completed an additional survey on treatment beliefs three months later.
Motivation, Perception and Treatment Beliefs
Measures regarding motivation to participate in the study (question 1 in Supplemental Table 1 ) and perceptions about genetic testing (Supplemental Table 2 ) were adapted from Gollust et al. (Gollust et al. 2012 ) and modified to include 'CHD'. The questions on this survey were scored on a 3-point Likert scale from Bnot important^(receiving a score of 1) to Bvery important( receiving a score of 3). Additional questions were added to the motivation survey (questions 2-5 in Supplemental Table 1 ) to assess motivation for out-of-pocket payment for genetic testing, recommending genetic testing to friends or family and awareness of clinical trials related to such testing. Questions 2-4 were scored on a 5-point Likert scale from Bstrongly disagree^(receiving a score of 1) to Bstrongly agree^(receiving a score of 5). Different Likert scales were employed to analyze answers for these questions primarily adapted from previously established surveys.
Measures of perception about genetic testing were scored on 4-point Likert scale from Bstrongly disagree^(receiving a score of 1) to Bstrongly agree^(receiving a score of 4). The average total score was calculated to compare the groups. Individual statements were grouped to agree/strongly agree and disagree/ strongly disagree for analysis. As such, survey statements towards perception included both the favorable and unfavorable information based on current genetic information.
The survey on treatment beliefs (Supplemental Table 3 ) was also adapted from literature (J. S. Roberts and Connell 2000) and similarly modified to include CHD. The measures were scored on a 5-point Likert scale from Bnot likely at all^(receiving a score of 1) to Bvery likely^(receiving a score of 5).
Statistical Analysis
All data analyses were performed using the SAS software. Continuous variables were expressed as mean ± SD; dichotomous variable were expressed as counts and percentages. Fisher's exact, and Chi-squared tests were performed as appropriate for binary variables and t test for continuous baseline sociodemographic data. Linear and ordinal logistic regression analyses were performed to analyze mean total ratings and individual ratings for each statement measured in the categories of interest (motivation, perception and treatment beliefs). Pearson's correlation coefficient was calculated to determine correlations among participants' perceptions, motivations, and treatment beliefs. A p-value of less than 0.05 was considered statistically significant.
Results
Participant Characteristics
A total of 216 participants were enrolled after initial screening, and 207 completed the first and second visits (Fig. 1) ; 103 participants were randomized to the CRS arm and 104 to the GRS arm. By the third visit, there were 100 participants in the CRS arm, and 103 in GRS arm; 11 participants in the CRS arm did not complete the final treatment beliefs survey. Baseline Table 1 . In both groups, the average age of the participants was approximately 60 years, and a little more than half of the participants were female. More than 50% of the participants had college or higher education. 25-30% of the participants had family history of CHD. There were no significant differences between the groups.
Motivation to Participate in the Study and Recommend Genetic Testing to Others
The motivation survey was administered at 3 months after risk disclosure. The majority of participants indicated curiosity about their genes, understanding their own and their children's risk of heart disease, desire to improve health, and altruism as reasons for their motivation to participate in the study (Table 2 ). There were no significant differences between the CRS and GRS arms regarding motivation to participate in the study, with one exception. Participants in the GRS arm indicated a greater desire to find ways to improve their health as motivation for study participation (OR: 0.53(95%CI:0.29, 0.93), p = 0.028). Participants in the GRS arm were also more willing to recommend genetic testing to friends and family (9.95 ± 0.70 vs. 10.52 ± 0.88, p = 0.046) ( Table 3 ). The vast majority of participants in both the CRS and GRS groups indicated awareness of clinical trials (96% vs. 97%, p = 0.549).
Perception about Genes and Genetic Testing
Surveys on perception were obtained at 3 months after risk disclosure. There was no difference in perception about genetic testing between the two groups (15.29 ± 0.39 vs. 15.12 ± 40, p = 0.835). Overall, participants in both groups had a favorable perception towards genes and genetic testing (Table 4) . However, participants in both groups had a low favorable score for the following questions: BThere are no risks to being in this study( 21% in CRS vs. 18. 4% in GRS, p = 0.779), BThe results will tell me what medications to take^(53% in CRS vs. 46.1% in GRS, p = 0.399); BI will learn about risk I can do nothing about^(58% in CRS vs. 62.1% in GRS, p = 0.647). In addition, 
Treatment Beliefs
Treatment beliefs surveys were obtained 6 months after risk disclosure. The majority of participants did not believe that there would be a cure for CHD within 5 years of survey completion or within their lifetime (Table 5) . Most believed there would be further advances in symptom relief and prevention for CHD. In the CRS arm, after disclosure of GRS at their fourth visit, optimism towards treatment beliefs decreased (mean difference: -1.01, 95% CI: -1.94, −0.08, p = 0.04). Treatment beliefs were weakly correlated with motivation to participate in the study (r = 0.18, p = 0.009), which in turn also weakly correlated with recommending tests to family and friends (r = 0.30, p = 0.001).
Discussion
In this study of genetic risk disclosure for CHD, the majority of participants were motivated to participate in genetic testing and had favorable perceptions about such testing. Participants who received a GRS for CHD were also more curious to find ways to improve their health and recommend testing to family and friends. Both study groups expressed similar optimism towards future treatment for CHD. Understanding motivation, perception, and treatment beliefs related to genetic testing for common diseases is crucial to integrate genomics in the advancement of individualized care, particularly for prevention of disease. Motivation to undergo genetic testing depends on individuals' desire to know about the disease, cost, potential harm, and treatment benefits related to the test. Factors such as curiosity, health improvement, concern about the health of their children and altruism have been revealed as motivating reasons for individuals who participated in genetic testing for other diseases (Facio et al. 2011; Gollust et al. 2012) . Our findings are consistent with the motivations for participating in genetic research reported by these studies. A desire to know about their genetic risk to improve health was borne out as a motivating factor in this study, consistent with results from early adopters of genetic testing in prior studies (Gollust et al. 2012; McGuire et al. 2009 ). More than 97% of the participants in our study indicated awareness of clinical trials, which may bode well for recruitment for future studies. Concern about the health of their children was also confirmed as a motivating factor in our study. The results are mixed on whether disclosing genetic risk impacts motivation to adopt healthy behaviors (Grant et al. 2009; Marteau et al. 2010; Sanderson et al. 2010; Scheinfeldt et al. 2016) . Participants who initially received their GRS reported greater motivation to adopt healthy behaviors in our study. In another study, participants reported increased exercise and healthy dietary choices after receiving a high genetic risk for CHD in a direct-toconsumer testing (Scheinfeldt et al. 2016) . However, in a prior report from the MI-GENES trial we demonstrated a greater likelihood of initiation of statin therapy, but not of a healthier diet or physical activity, in those who received their GRS relative to those who initially received their CRS alone (Kullo et al. 2016) . Thus, while, genetic risk disclosure studies on diabetes risk, lung cancer risk and smoking, obesity and skin cancer risk showed intent or motivation to adopt healthy behaviors, whether this leads to positive health outcomes remains to be seen (Branstrom et al. 2012; Grant et al. 2009; Kammin et al. 2015; Marteau et al. 2010; Sanderson et al. 2010) . Further, larger prospective studies would help us to understand whether this intention to change will lead to long-term positive health outcomes.
Individuals' perceptions about disease, potential tests, and treatment for the disease are based on complex interactions of knowledge about risk factors, socioeconomic status, and educational and cultural background (Katapodi et al. 2010) . Understanding perceptions about genetic testing for complex diseases such as CHD can help tailor screening for disease and individualize therapy. In general, studies have shown favorable perceptions towards genetic testing for known heritable diseases (Branstrom et al. 2012; Grant et al. 2009; Hardcastle et al. 2015) , but perceptions about the role of genetics in common complex diseases (which have multiple loci of inheritance) may vary (Waxler et al. 2012 ). In our study, the majority of participants had overall favorable perceptions about genetic testing for CHD. However, unfavorable perceptions including a fear of having no control over the knowledge of their results, experiencing possible harms from genetic testing, and being uncertain of the role of genetic testing on medication use were identified. Contrary to the results from prior US and European studies, nearly 90% of the participants in both the groups disagreed with the statement that genetic testing might limit their ability to find insurance (Gollust et al. 2012; Haga et al. 2013; Henneman et al. 2013) . This change in the perception is likely from increased awareness of the federal Genetic Information Nondiscrimination Act (GINA) legislation protecting against the use of genetic information by health insurers and employers (Prince and Roche 2014) . Counseling prior to testing may help alleviate some of these fears, as well as any misperceptions about genetic testing.
Beliefs about future advancement in CHD therapies are a potential motivation to engage subjects in genetic testing research and positive health behaviors. Conversely, unrealistic optimism or pessimism towards genetic testing for complex disease such as CHD may generate feeling of invulnerability or feeling of fatalism, respectively (Clarke et al. 2000; R. E. Collins et al. 2011 ). In our study, participants in both groups were similarly optimistic towards prevention, advancing care of, and cure for CHD. There was a slight decrease in optimism towards finding a cure for CHD after GRS disclosure by a study coordinator in participants who initially only received their CRS. This suggest the need for a genetic counselor for risk disclosure to help avoid potentially unfavorable or inaccurate interpretation of genetic testing results for complex diseases such as CHD.
Limitations of the Study
Our study has several limitations. Baseline motivation, perception, and treatment beliefs were not assessed to avoid excess participant burden. Study participants were relatively well educated (60% had college degree) whites. Results should therefore be generalized with caution. As with any studies that involve reporting and recall of information, health information seeking and sharing in the interim from baseline or between risk disclosure and survey administration may influence perceptions and motivation, but this should have affected participants in both groups similarly.
Practice Implications
Recent advances in genetics have identified multiple genetic variants associated with CHD (Deloukas et al. 2013; Nikpay et al. 2015) . Incorporating these genetic variants to calculate a genetic risk score could potentially refine estimates of CHD risk and facilitate early initiation of preventive measures to decrease the risk of adverse cardiovascular events. To adopt genetic testing in clinical settings, it is important to understand individuals' motivation and perceptions towards such testing for common complex diseases, such as CHD. In the present study, participants were motivated and had positive perceptions toward adopting genetic testing for estimation of their CHD risk. These findings are consistent with earlier studies, particularly those with early adopters of genetic testing and in select patient populations with hereditary or cancer syndromes (Gollust et al. 2012; Leenen et al. 2016 ).
Perceptions about the role of genetic testing for complex diseases such as CHD may vary (Waxler et al. 2012) . Unfavorable perceptions including fear of having no control over the knowledge of one's results, experiencing possible harms from genetic testing, and being uncertain of the role of genetic testing on medication use were identified in our study. These fears seem to attenuate with genetic counseling prior to the disclosure of test results.
As CHD risk is modifiable with lifestyle changes, proper management of risk factors, and initiation of statin therapy, it is important that patients' risk for major cardiovascular events is accurately estimated for primary prevention. Incorporating a genetic risk score may improve the accuracy of CHD risk estimates and genetic counseling prior to disclosing test results may help alleviate negative perceptions.
Research Recommendation
With advances in genomic medicine, it is likely that additional genetic risk variants for CHD will be identified, which may improve current risk prediction algorithms for CHD. It is imperative to assess motivation, perceptions, and treatment beliefs in multiple ethnic groups, various socioeconomic strata and education levels before testing can be widely adopted in clinical settings for advancement of precision medicine for CHD.
Conclusion
In the MI-GENES trial, motivation to participate in a genetic study for CHD and perception of genetic testing were positive overall, regardless of GRS disclosure. Nevertheless, disclosure of GRS was associated with a greater likelihood for the desire to find ways to improve health and willingness to recommend genetic testing to friends and family. Disclosure of genetic risk for a complex disease may therefore motivate participation in genetic trials and recommendation of genetic testing in health promotion behaviors. Understanding of perceptions, motivation and treatment beliefs towards genetic testing for CHD will facilitate further research in genetics and precision medicine for CHD.
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